Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AL 002

Next Previous
Drug Profile

AL 002

Alternative Names: AL 002; AL 002a; AL-002c

Latest Information Update: 23 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie; Alector
  • Class Antibodies; Antidementias; Immunotherapies; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action TREM2 protein-stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 31 Jan 2025 Alector and AbbVie terminates research and development agreement for development of antibody therapeutics for Alzheimer's disease and Neurodegenerative disorders
  • 31 Jan 2025 Alector terminates the phase II long-term extension trial for Alzheimer's disease (Early-stage disease, In adults, In elderly) in Argentina, Australia, Canada, Germany, Italy, Netherlands, Poland, Spain and the US and UK, as INVOKE-2 trial failed to meet the primary endpoint and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints (NCT05744401)(EudraCT2022-002987-57)
  • 26 Nov 2024 Efficacy and adverse event data from the phase II INVOKE-2 trial released by Alector

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top